Navigation Links
Human breast tumors' 'microenvironment' primes them for metastasis

The environment within primary breast tumors can empower cells that break free and enter the bloodstream to successfully invade other organs, researchers report in the April 4th Cell, a publication of Cell Press.

Specifically, through studies of hundreds of human breast tumors, the researchers found evidence that the cytokine TGF in the tumor microenvironment primes breast cancer cells for metastasis to the lungs, one of the most common sites for the spread of breast and other cancers. TGF signaling is often activated within tumors as a natural response to the oxygen starved and inflammatory conditions that come with tumor progression.

The microenvironment of a tumor is not just cancer cells, but all other cell types that congregate there, said Joan Massague of Memorial Sloan-Kettering Cancer Center in New York. In recent years, he said, increasing attention has been paid to the impact those other body cells can have on the tumor locally, through their affects on blood vessel growth, the ability of cancer cells to enter the circulation, and so on.

Our study shows that it doesnt end there, he said. The cancer cells can come out with instructions that serve them in the long run.

The research team analyzed the expresssion of all 20,000 genes in the human genome within hundreds of primary breast tumors. Those tumors fell within two classical groups based on whether their estrogen receptor status was positive or negative (ER+ or ER-). In both tumor groups, the researchers found that about 40 percent of the tumors bore the genetic signature of TGF?s influence.

They found that TGF exposure didnt seem to make any difference to the risk of cancer spread in ER+ tumors. In ER- tumors, however, TGF correlated markedly with an increased risk for metastasis to the lung, but not to bone. In other words, Massague said, context matters."

The researchers continued to dig, ultimately uncovering the fascinating biology behind that correlation. They found that the TGF exposure in ER- tumors leads to an increase in a second cytokine within the tumor cells, called angiopoietin-like 4 (ANGPTL4). Once those cells escape the tumor and lodge in the lungs, ANGPTL4 disrupts the connections between cells in the thin capillaries there. That separation of cell-cell contacts allows the cancer cells to cross the vessel wall and pass into the lung proper, Massague said.

The findings suggest that TGF, or perhaps even better ANGPTL4, might serve as targets for drugs aimed at preventing the spread of breast cancer to the lungs. The TGF signature could also offer a means of predicting those breast cancer patients at particularly high risk for developing metastatic lung cancer so that they might be monitored more closely and treated more aggressively with existing drugs.

Massague said he suspects the new findings are but one example of a more general cancer phenomenon.

Entering and colonizing an organ requires of a tumor cell a number of special abilities, he said. After all, our bodies are not made up of cells that are allowed to go anywhere as tumor cells [sometimes] manage to do. Weve shown that factors within primary tumors can act on cancer cells to enhance their ability to selectively spread to other tissues.


Contact: Cathleen Genova
Cell Press

Related medicine news :

1. General Dynamics Itronix Donates Computers to Humanitarian Expedition Fighting Malaria in Africa
2. Families of children with cancer support human tissue research, study finds
3. Mayo Clinic Proceedings Examines a Possible Link Between Bacteria Found in the Human Digestive System and Obesity
4. Humans have more distinctive hearing than animals, Hebrew U study shows
5. Dogs and Cats Need Omega-3 Fatty Acids Just as Humans Do - Nordic Naturals Offers Premium Fish Oil to Supplement Pets Diet!
6. UCLA researchers examine human embryonic stem cell genome
7. 10th Annual Human Resources Conference, June 4-6: Sharing New Insights on Workforce Planning
8. Batesville Holdings, Inc., Appoints Doug Wilson Senior Vice President Human Resources
9. Researchers urge ethics guidelines for human-genome research
10. Source Endurance and So High Sports Announce Research Alliance for Physiology and Human Performance
11. Monkey Brain Gives Clues to Human Interaction
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Halo Labs announces the European launch of their new low ... MIBio 2017 in Cambridge, U.K on October ... biopharmaceutical samples with unprecedented speed and sensitivity while using far less ... Imaging. ... analysis system ...
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: